Abuse Liability/Potential HAL/ HAP
Any new drug that has the potential to target sites or permeate the central nervous system requires an assessment of its abuse and dependence liability. Lotus has historically focused the growth of its services, expertise, and regulatory knowledge in analgesics to successfully partner with biopharmaceutical companies to execute clinical trials across acute and chronic pain indications. Each of our pain clients are looking for a treatment option for the more than 50 million Americans that suffer from chronic pain, and exponentially more that will endure acute pain from surgical procedures without falling victim to addiction. The importance of Human Abuse Probability (HAP) research is not limited to analgesics, but it has given Lotus and our Sponsors a huge advantage in quickly and effectively running these important trials. Lotus, along with our affiliated nationally recognized and respected site in Ohio (Ohio Clinical Trials, or OCT) understand the unique challenges of this type of trial. Human abuse potential studies run in patients who are nondependent recreational opioid users, assess drug likeability at high doses, above the therapeutic range. Lotus and OCT have almost immediate access to this patient group and can enroll these studies faster than any other CRO.